Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 6, 2005, Pages 569-577

  Zhou, Qingyu ^a   Olivo, Malini ^a   Lye, Karen Yee Kar ^a   Moore, Shirley ^a   Sharma, Amarnath ^b   Chowbay, Balram ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b PFIZER INC   (United States)

Author keywords

Antiangiogenic agents; Nasopharyngeal carcinoma; Photodynamic therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CYCLOOXYGENASE 2; HYPERICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SEMAXANIB; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HYPOXIA; MALE; MICROVASCULATURE; MONOTHERAPY; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TUMOR RECURRENCE; TUMOR XENOGRAFT; UPREGULATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION; INDOLES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PERYLENE; PHOTOCHEMOTHERAPY; PROTEIN-TYROSINE KINASES; PROTEINS; PYRROLES; SURVIVAL RATE;

EID: 26444525737     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-1017-0     Document Type: Article

References (40)

1. Ausprunk DH, Folkman J (1997) Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14:53-65
2. Chan WS, Brasseur N, La Madeleine C, van Lier JE (1996) Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin: tumor cell survival and blood flow. Anticancer Res 16:1887-1892
3. Chen B, Zupko I, de Witte PA (2001) Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy. Int J Oncol 18:737-742
4. Chen Q, Huang Z, Chen H, Shapiro H, Beckers J, Hetzel FW (2002) Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol 76:197-203
5. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L (2003) VEGF-receptor signal transduction. Trends Biochem Sci 28:488-494
6. Denko NC, Fontana LA, Hudson KM, Sutphin PD, Raychaudhuri S, Altman R and Giaccia AJ (2003) Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22:5907-5914
7. Dimitroff CJ, Klohs W, Sharma A, Pera P, Driscoll D, Veith J, Steinkampf R, Schroeder M, Klutchko S, Sumlin A, Henderson B, Dougherty TJ, Bernacki RJ (1999) Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 17: 121-135
8. Dougherty TJ (1996) A brief history of clinical photodynamic therapy development at Roswell Park Cancer Institute. J Clin Laser Med 14:219-221
9. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. Natl Cancer Inst 90:889-905
10. Du HY, Bay BH, Olivo M (2003) Biodistribution and photodynamic therapy with hypericin in a human NPC murine tumor model. Int J Oncol 22:1019-1024
11. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ (2000) Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60:4066-4069
12. Folkman J (1995) Tumour angiogensis. In: Mendelsohn J, Howley PM, Liotta MA (eds) Themolecular basis of cancer. WB Sanders, Philadelphia, pp 206-232
13. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106
14. Henderson BW, Dougherty TJ (1992) How does photodynamic therapy work?. Photochem Photobiol 55:145-157
15. Henderson BW, Vaughan L, Bellnier DA, van Leengoed H, Johnson PG, Oseroff AR (1995) Photosensitization of murine tumor, vasculature and skin by 5-aminolevulinic acid-induced porphyrin. Photochem Photobiol 62: 780-789
16. Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y, Cherrington J, McMahon G, Shibuya M, Kuwano M, Ono M (2002) Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther 1:295-302
17. Kessel D (1990) HPD structure and determinants of localization. In: Kessel D (ed) Photodynamic therapy of neoplastic diseases. CRC, Boca Raton, pp 1-14
18. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington JM (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160
19. Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM (2002) SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 16:681-690
20. Lofgren LA, Hallgren S, Nilsson E, Westerborn A, Nilsson C, Reizenstein J (1995) Photodynamic therapy for recurrent nasopharyngeal cancer. Arch Otolaryngol Head Neck Surg 121:997-1002
21. Lukiw WJ, Ottlecz A, Lambrou G, Grueninger M, Finley J, Thompson HW and Bazan NG (2003) Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci 44:4163-4170
22. Lund EL, Bastholm L, Kristjansen PE (2000) Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 6:971-978
23. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL,Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM (2000) Development of SU5416, a selective small molecule inhibitor of VEGFreceptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drugs 15:29-41
24. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM (2000) The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6:4848-4858
25. Nelson JS, Liaw LH, Orenstein A, Roberts WG, Berns MW (1988) Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. J Natl Cancer Inst 80:1599-1605
26. Ning S, Laird D, Cherrington JM, Knox SJ (2002) The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157:45-51
27. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF (2004) Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 10:4048-4054
28. Schouwink H, Oppelaar H, Ruevekamp M, van der Valk M, Hart G, Rijken P, Baas P, Stewart FA (2003) Oxygen depletion during and after mTHPC-mediated photodynamic therapy in RIF1 and H-MESO1 tumors. Radiat Res 159:190-198
29. Semenza GL (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35:71-103
30. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59:5412-5416
31. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ (2001) Photodynamic therapy in oncology. Expert Opin Pharmacother 2:917-927
32. Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, Karrison T, Vokes EE (2004) A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 10:3365-3370
33. Star WM, Marijnissen HP, van den Berg-Blok AE, Versteeg JA, Franken KA, Reinhold HS (1986) Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 46:2532-2540
34. Stanbridge EJ, Nowell PC (1990) Origins of human cancer revisited. Cell 63:867-874
35. Tong MC, van Hasselt CA, Woo JK (1996) Preliminary results of photodynamic therapy for recurrent nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 253:189-192
36. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, Ullrich A, Fong TA (1999) Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1:31-41
37. Weinberg RA (1989) Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49:3713-3721
38. Wenger RH, Gassmann M (1997) Oxygenes and the hypoxia-inducible factor-1. Biol Chem 378:609-616
39. Yu MC, Yuan JM (2002) Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12:421-429
40. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J, Cooper M, Hannah A, Garcia-Manero G, Faderl S, Kantarjian H, Cherrington J, Albitar M, Giles FJ (2004) Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10:88-95